Viking Therapeutics (NASDAQ: VKTX) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may ...

Viking Therapeutics stock is down 52% over the trailing-12-month period. However, many Wall Street analysts remain ...

Partnership is expected to support Phase III development of VK2735 in patients with obesity and metabolic disorders amid ...

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...

Viking is in the midst of a Phase 2a dosing trial of VK2735, with a data readout expected in the second half of the year. The company is expected to launch a Phase 3 trial of VK2735 in injectable ...

Analysts acknowledged the long-term manufacturing deal could dull Viking’s takeout prospects but hailed it as a smart move to ...

Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...

After Viking Therapeutics (VKTX) announced a multi-year manufacturing agreement with CordenPharma to support the commercialization of VK2735, ...

Viking Therapeutics (VKTX), the developer of a promising experimental weight-loss drug, has announced a multi-year ...

The agreement provides Viking with sufficient long-term supply of both subcutaneous and oral VK2735 product forms to support a potential multi-billion-dollar annual product opportunity.

The deal comes as Viking prepares to start late-stage testing of an injectable form of the therapy, VK2735, by the end of June. The company said in February it has enough drug supply to complete its ...